Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Von Eschenbach Nomination Criticized By Conservatives Over Plan B Switch

This article was originally published in The Tan Sheet

Executive Summary

The nomination of Andrew von Eschenbach to FDA full commissioner is now being challenged by conservatives, in reaction to the agency's reconsideration of Barr Labs' switch application for emergency contraceptive Plan B

You may also be interested in...



EC Foes Cite Study Showing More Access Fails To Cut Abortions, Pregnancies

Increased access to emergency contraception (EC) is not reducing unintended pregnancy rates, and further research is needed to determine how best to yield a public benefit from EC access, a meta-analysis finds

EC Foes Cite Study Showing More Access Fails To Cut Abortions, Pregnancies

Increased access to emergency contraception (EC) is not reducing unintended pregnancy rates, and further research is needed to determine how best to yield a public benefit from EC access, a meta-analysis finds

EC Foes Cite Study Showing More Access Fails To Cut Abortions, Pregnancies

Increased access to emergency contraception (EC) is not reducing unintended pregnancy rates, and further research is needed to determine how best to yield a public benefit from EC access, a meta-analysis finds

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel